000130247 001__ 130247
000130247 005__ 20240123131022.0
000130247 0247_ $$2doi$$a10.1016/j.amjcard.2016.11.025
000130247 0248_ $$2sideral$$a98207
000130247 037__ $$aART-2017-98207
000130247 041__ $$aeng
000130247 100__ $$0(orcid)0000-0002-1894-1621$$aPérez-Calahorra, S.
000130247 245__ $$aValue of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients
000130247 260__ $$c2017
000130247 5203_ $$aFamilial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of cardiovascular disease (CVD), although with high variability among subjects. Currently, CVD stratification tools for heterozygous FH (HeFH) are not available. A definition of severe HeFH has been recently proposed by the International Atherosclerosis Society (IAS), but it has not been validated. Our study aims to see clinical characteristics and prevalence of CVD in subjects defined as severe HeFH by IAS criteria. Probable or definite HeFH introduced in the Dyslipidemia Registry of Spanish Arteriosclerosis Society were analyzed by the IAS criteria. Univariate and multivariate analysis was used to assess the association of CVD with the IAS criteria. About 1, 732 HeFH cases were analyzed. Severe HeFH had higher prevalence of familial history of CVD, personal history of tendon xanthomas, LDL cholesterol, and CVD than nonsevere HeFH. A total of 656 (77.1%) and 441 (50.1%) of men and women, respectively, fulfilled the IAS criteria of severe HeFH. In the univariate analysis, subjects defined as severe HeFH showed odds ratio 3.016 (95% CI 3.136 to 4.257, p 400 mg/dl had a statistically significant association with CVD odds ratio 8.76 (95% CI 3.90 to 19.69, p <0.001). In conclusion, the IAS definition of severe HeFH is not significantly associated with CVD when adjusted for classic risk factors. Risk stratification in HeFH is an important issue, but the proposed criteria do not seem to solve this problem.
000130247 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130247 590__ $$a3.171$$b2017
000130247 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b49 / 128 = 0.383$$c2017$$dQ2$$eT2
000130247 592__ $$a1.93$$b2017
000130247 593__ $$aCardiology and Cardiovascular Medicine$$c2017$$dQ1
000130247 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000130247 700__ $$aSánchez-Hernández, R. M.
000130247 700__ $$aPlana, N.
000130247 700__ $$aMarco-Benedi, V.
000130247 700__ $$aPedro-Botet, J.
000130247 700__ $$aAlmagro, F.
000130247 700__ $$aBrea, Á.
000130247 700__ $$aAscaso, J. F.
000130247 700__ $$aLahoz, C.
000130247 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000130247 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000130247 773__ $$g119, 5 (2017), 742-748$$pAm. j. cardiol.$$tAMERICAN JOURNAL OF CARDIOLOGY$$x0002-9149
000130247 8564_ $$s506714$$uhttps://zaguan.unizar.es/record/130247/files/texto_completo.pdf$$yVersión publicada
000130247 8564_ $$s3224521$$uhttps://zaguan.unizar.es/record/130247/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130247 909CO $$ooai:zaguan.unizar.es:130247$$particulos$$pdriver
000130247 951__ $$a2024-01-23-12:43:15
000130247 980__ $$aARTICLE